From: Renal AA-amyloidosis in intravenous drug users – a role for HIV-infection?
Age (years) | 41 (33 – 46) |
---|---|
Male – n (%) | 15 (62.5%) |
Self-reported time after initiation of IVDU (years) | 22 (13 – 30) |
Self-reported duration of IVDU in years | 17 (8 – 25) |
History of opioid maintenance therapy | 12 (50%) |
Chronic hepatitis B | 1 (4.2%) |
Past HBV exposure | 7 (29.2%) |
Chronic hepatitis C | 21 (87.5%) |
HIV infection | 10 (41.7%) |
Renal disease by biopsy-findings – n (%) | |
AA-amyloidosis | 12 (50.0%) |
Membranoproliferative GN Type I | 5 (20.8) |
Nephrosclerosis | 2 (8.3%) |
Extracapillary proliferative GN | 2 (8.3%) |
Focal segmental Glomerulosclerosis | 1 (4.2%) |
Chronic tubulointerstitial nephritis | 1 (4.2%) |
Lupus nephritis Class IV | 1 (4.2%) |